Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.69 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 10/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.47 |
| ▸ | CDC42 | P60953 | 1/20 | 0.47 |
| ▸ | RAC1 | P63000 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245190 | 1.00 | CXCR2 (0.69) | CXCR2CXCR1AKR1C3PTGS2AKR1C2 | |
| SCHEMBL1345636 | 1.00 | CXCR2 (0.69) | CXCR2CXCR1AKR1C3PTGS2AKR1C2 | |
| SCHEMBL246051 | 0.87 | CXCR2 (0.66) | CXCR2CXCR1AKR1C3PTGS2AKR1C2 | |
| SCHEMBL4414662 | 0.87 | CXCR2 (0.66) | CXCR2CXCR1AKR1C3PTGS2AKR1C2 | |
| SCHEMBL4747670 | 0.87 | CXCR2 (0.66) | CXCR2CXCR1AKR1C3PTGS2AKR1C2 | |
| SCHEMBL252024 | 0.87 | CXCR2 (0.66) | CXCR2CXCR1AKR1C3PTGS2AKR1C2 | |
| SCHEMBL18770103 | 0.86 | AKR1C3 (0.64) | CXCR2CXCR1AKR1C3PTGS2AKR1C2 | |
| SCHEMBL1822574 | 0.86 | CXCR2 (0.68) | CXCR2CXCR1AKR1C3PTGS2AKR1C2 | |
| SCHEMBL251658 | 0.84 | CXCR2 (0.75) | CXCR2CXCR1 | |
| SCHEMBL250803 | 0.84 | CXCR2 (0.75) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4686469-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF DIABETES-ASSOCIATED COMORBIDITIES | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | disclosed |
| EP-4686472-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | disclosed |
| EP-4678171-A1 | SYSTEMICALLY-ADMINISTERED CXCL8 INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici SpA (IT) | 2026-01-14 | — | — | EP | disclosed |
| EP-4563594-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF TUMORS WITH LOW STROMAL CAV1 LEVELS | Dompe' Farmaceutici SpA (IT) | 2025-06-04 | — | — | EP | disclosed |
| EP-4397305-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | disclosed |
| US-20120316169-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.A. (IT) | 2012-12-13 | — | — | US | disclosed |
| EP-2493846-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompe S.p.A. (IT) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051375-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.A. (IT) | 2011-05-05 | — | — | WO | disclosed |
| EP-2316820-A1 | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2011-05-04 | — | — | EP | disclosed |
| EP-2229942-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| EP-1776336-B1 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316169-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BDKRB2, BDKRB1, CNR2 | CXCR2 271/4885CXCR1 992/4885AKR1C3 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.